• 6 min read
• Published on 21 December 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
Let's be honest, it wasn't long ago we were all staring at empty supermarket shelves, wondering if the world was about to run out of loo roll. A more serious, if less discussed, panic was brewing in the halls of government. What if we couldn't get our hands on essential medicines? It turns out a startling amount of our pharmaceutical supply chain was stretched precariously across the globe. So, it seems a deal has been struck. A rather enormous one, in fact. And for investors, I think it pays to understand what’s really going on behind the curtain.
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
At its heart, this is a classic political trade off. Nine of the world’s largest pharmaceutical companies have shaken hands with the government, agreeing to what essentially amounts to price concessions on certain drugs. In return, they get juicy policy benefits, like tariff exemptions, and a clear runway for the future. The headline figure is a staggering $150 billion committed to bringing research and manufacturing back to home soil over the next decade.
This isn't your typical market cycle. This is a policy driven tidal wave. Companies like Merck and Amgen aren't just building a new warehouse because sales are up. They are fundamentally re-wiring their operations because the political and economic winds have changed direction entirely. To me, it looks less like a free market decision and more like a national security directive wrapped in a business deal. The government gets its drug affordability talking points and a more secure supply chain. The pharma giants get a predictable environment to make huge, long term investments.
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
Now, here is where it gets interesting for those of us not running a multi billion pound drug company. When a giant new factory is built, it isn’t just the factory owner who profits. It’s the tool suppliers, the catering vans, and the local estate agents. The same principle applies here, but on a much grander scale. This wave of investment creates opportunities for a whole ecosystem of companies.
Consider Thermo Fisher Scientific, a company that provides the sophisticated instruments every new laboratory will need. Or the contract research firms like IQVIA, which will likely see a surge in demand as drug development accelerates domestically. These companies provide the essential picks and shovels for this pharmaceutical gold rush. As new plants are built, they will require cutting edge automation, which is where firms like Rockwell Automation come in. It’s a vast, interconnected web, and the initial investment is just the start of the story. You can find a deeper analysis in this guide, Pharma Reshoring Explained | Manufacturing Investment, which details the intricate manufacturing connections.
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
Of course, no deal this large comes without its share of headaches. Investing billions whilst simultaneously accepting lower prices on some of your products is a tricky balancing act that could certainly squeeze margins. There’s also the small matter of politics. These agreements are based on the current government's priorities. What’s to stop a new administration from tearing it all up and starting again? That’s a risk that cannot be ignored.
Furthermore, building a state of the art pharmaceutical plant isn’t like putting up a garden shed. It takes years of construction, planning, and regulatory approvals. Anyone expecting immediate returns from the big pharma companies themselves might be in for a long wait. The most significant challenge, I suspect, will be finding the people. The industry requires an army of highly skilled scientists and engineers. A sudden surge in demand could create a fierce war for talent, pushing up wages and adding another layer of cost. This is a long term play, with potential rewards matched only by considerable risks.
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
View the full Basket:Pharma Reshoring Explained | Manufacturing Investment
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article